San Francisco – September 19, 2016 – Cooley advised BioMarin Pharmaceutical on its follow-on offering of 7,500,000 shares of common stock for gross proceeds of $720 million.
BioMarin, which trades on The NASDAQ Global Select Market as “BMRN,” develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. Its product portfolio consists of five approved products and multiple clinical and pre-clinical product candidates.
Goldman, Sachs & Co. and BofA Merrill Lynch acted as joint book-running managers for the offering.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.